Amylin Analog · Metabolic Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
Cagrilintide is a long-acting synthetic analog of human amylin — the peptide hormone co-secreted with insulin from pancreatic beta cells. It activates amylin receptors in the brain to regulate satiety, gastric emptying, and glucose homeostasis. The CagriSema combination (Cagrilintide + Semaglutide) has demonstrated up to 25% weight loss in Phase 3 research, establishing it as a critical compound for dual-mechanism metabolic studies.
Q: Why combine Cagrilintide with GLP-1 agonists?
A: Amylin and GLP-1 receptors are in overlapping but distinct brain regions. Research suggests combining both mechanisms produces additive or synergistic satiety effects beyond either pathway alone.
Q: How does Cagrilintide differ from pramlintide?
A: Pramlintide requires multiple daily doses. Cagrilintide is engineered for once-weekly dosing in research protocols, making it practical for longitudinal study designs.
Q: What are amylin receptors?
A: Complexes of calcitonin receptors with receptor activity-modifying proteins (RAMPs), expressed in the area postrema and hypothalamus — key regions regulating appetite and energy balance.
Related Research: Semaglutide Research Peptide | 2026 Metabolic Research Update | Tirzepatide Research Peptide
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
